Temporary blockade of the tumor necrosis factor receptor signaling pathway impedes the spread of scrapie to the brain

Citation for published version:

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Journal of Virology

Publisher Rights Statement:
Copyright © 2002, American Society for Microbiology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Temporarily Blockade of the Tumor Necrosis Factor Receptor Signaling Pathway Impedes the Spread of Scrapie to the Brain

Neil A. Mabbott, Gillian McGovern, Martin Jeffrey, and Moira E. Bruce

Neuropathogenesis Unit, Institute for Animal Health, Edinburgh EH9 3JF, and Veterinary Laboratories Agency—Lasswade, Pentlands Science Park, Midlothian EH26 0PZ, Scotland, United Kingdom

Received 3 December 2001/Accepted 12 February 2002

Although the transmissible spongiform encephalopathies (TSEs) are neurodegenerative diseases, their agents usually replicate and accumulate in lymphoid tissues long before infection spreads to the central nervous system (CNS). Studies of a mouse scrapie model have shown that mature follicular dendritic cells (FDCs), which express the host prion protein (PrP\textsubscript{sc}), are critical for replication of infection in lymphoid tissues. In the absence of mature FDCs, the spread of infection to the CNS is significantly impaired. Tumor necrosis factor alpha (TNF-\alpha) secretion by lymphocytes is important for maintaining FDC networks, and signaling is mediated through TNF receptor 1 (TNFR-1) expressed on FDCs and/or their precursors. A treatment that blocks TNFR signaling leads to the temporary dedifferentiation of mature FDCs, raising the hypothesis that a similar treatment would significantly delay the peripheral pathogenesis of scrapie. Here, specific neutralization of the TNFR signaling pathway was achieved through treatment with a fusion protein consisting of two soluble human TNFR (huTNFR) (\(\beta\)80) domains linked to the Fe portion of human immunoglobulin G1 (huTNFR:Fc). A single treatment of mice with huTNFR:Fc before or shortly after intraperitoneal injection with the ME7 scrapie strain significantly delayed the onset of disease in the CNS and reduced the early accumulation of disease-specific PrP\textsubscript{sc} in the spleen. These effects coincided with a temporary dedifferentiation of mature FDCs within 5 days of huTNFR:Fc treatment. We conclude that treatments that specifically inhibit the TNFR signaling pathway may present an opportunity for early intervention in peripherally transmitted TSEs.

The transmissible spongiform encephalopathies (TSEs), or “prion diseases,” are infectious neurodegenerative diseases that affect humans and both wild and domestic animals. The host prion protein (PrP\textsuperscript{sc}) is critical for TSE agent replication (8) and accumulates in diseased tissues as an abnormal, detergent-insoluble, relatively proteinase-resistant isoform, PrP\textsuperscript{sc} (4). Although the precise nature of the TSE agent is uncertain (13), PrP\textsuperscript{sc} copurifies with infectivity and is considered to be a major component of the infectious agent (41).

Natural TSEs, including sheep scrapie, bovine spongiform encephalopathy (BSE), chronic wasting disease in mule deer and elk, and variant Creutzfeldt-Jakob disease (vCJD) in humans, are considered to be acquired peripherally. For example, the emergence of vCJD in the United Kingdom population is almost certainly due to consumption of BSE-contaminated tissues (7). Following peripheral exposure, TSE agents usually accumulate in lymphoid tissues long before infection spreads to the central nervous system (CNS). For example, after intragastric or oral challenge of rodents with scrapie, the infectious agent first accumulates in Peyer’s patches and gut-associated lymphoid tissues (2, 24). The detection of PrP\textsuperscript{sc} in Peyer’s patches and gut-associated lymphoid tissues of sheep with natural scrapie (1, 20) prior to detection in other lymphoid tissues and the CNS (46) implies that this disease is also acquired orally. Lymphoid tissues play an important role in transmission in some TSE models (17), but this tissue tropism may be agent strain dependent. Although acquired peripherally, BSE in cattle (43) and iatrogenic Creutzfeldt-Jakob disease in humans (21) appear to be confined to nervous tissues. However, within the lymphoid tissues of patients with vCJD (21) and most sheep with natural scrapie (45) or following experimental peripheral infection of rodents with scrapie (5, 29, 30, 33), early PrP\textsuperscript{sc} accumulation takes place on follicular dendritic cells (FDCs). Studies of mouse scrapie models have shown that mature FDCs are critical for replication in lymphoid tissues and that in their absence, neuroinvasion following peripheral challenge is significantly impaired (5, 29, 30, 35). From the lymphoid tissues, infectious agents spread to the CNS via peripheral nerves (19).

The FDC therefore presents a potential target for therapeutic intervention in peripherally acquired TSEs such as natural sheep scrapie and vCJD. Indeed, recent studies have demonstrated that treatments that temporarily interfere with the integrity (29, 35) or function (28) of FDCs also interfere with TSE pathogenesis. Signaling through lymphocyte-derived tumor necrosis factor alpha (TNF-\alpha) is critical for FDC development, as mice deficient in TNF-\alpha (TNF-\alpha\textsuperscript{−/−} mice) lack mature FDCs in lymphoid tissues (38). The effects of TNF-\alpha on FDC development are mediated via signaling through TNF receptor 1 (TNFR-1) expressed on FDCs and/or their precursors (44). Specific neutralization of the TNF-\alpha signaling pathway leads to the temporary inactivation of FDCs (31), suggesting that FDCs require constant stimulation from this cytokine to maintain their differentiated state. It has previously been shown that in the absence of mature FDCs in the lymphoid tissues of TNF-\alpha\textsuperscript{−/−} mice, susceptibility to peripheral challenge with scrapie is reduced (30). Therefore, in this study we sought to determine whether a treatment that temporarily...
blocks the TNF-α signaling pathway would delay the spread of scrapie to the CNS.

MATERIALS AND METHODS

huTNFR:Fc treatment. At the times indicated, C57BL mice (8 to 12 weeks old) were given a single intraperitoneal (i.p.) injection of 100 μg of a dimeric fusion protein containing the soluble human TNFR (huTNFR) (p80) domain linked to the Fc portion of human immunoglobulin G1 (huTNFR:Fc; Immunex Corp., Seattle, Wash.) (34) or 100 μg of polyclonal human immunoglobulin G (hu-Ig) (Sandoglobulin; provided by J. Browning, Biogen Inc., Cambridge, Mass.) as a control. To monitor the effects of treatment on FDC status, at the times indicated following treatment, two spleens were taken from each group and halved. One half was fixed in periodate-lysine-paraformaldehyde and embedded in paraffin wax for immunocytochemical detection of PrP (33) with the PrP-specific antiserum 1B3 (15). The other half was snap-frozen at the temperature of liquid nitrogen, and 6-μm-thick sections were cut on a cryostat. FDCs were visualized by staining with the FDC-specific monoclonal antiserum FDC-M2 (27) or 8C12 monoclonal antiserum to detect CD35 (Pharmingen, San Diego, Calif.). Immunolabeling was carried out with alkaline phosphatase coupled to the avidin-biotin complex (Vector Laboratories Inc., Burlingame, Calif.).

Scrapie inoculum. At the times indicated relative to treatment, mice were injected intracerebrally (i.c.) or i.p. with 20 μl of a 1.0, 0.1, or 0.01% (wt/vol) dilution of unspun brain homogenate from C57BL mice terminally affected with ME7 scrapie (20 μl of a 1.0% homogenate represents a dose of approximately 1 × 10^4 i.c. or 5 × 10^4 i.p. mice) infectivity. Immediately following treatment, animals were coded and assessed weekly for signs of clinical disease and killed at a standard clinical end point (16). Scrapie diagnosis was confirmed by histopathological assessment of vacuolation in the brain. Where indicated, some mice were sacrificed 70 days postchallenge, and their spleens were taken for further analysis. For the bioassy of scrapie infectivity, individual half spleens were prepared as 10% tissue homogenates in phosphate-buffered saline and 20 μl was injected i.c. into groups of 12 C57BL indicator mice. The titer of each spleen was determined from the mean incubation period for the assay mice with reference to established dose-incubation period response curves for scrapie-infected spleen tissue (11).

Immunoblot detection of PrP^Sc. The remaining half of each spleen collected 70 days postchallenge was prepared as previously described (12, 28, 30). In brief, before immunoblot analysis, spleen tissue homogenates were treated with 20 μg of proteinase K (to confirm the presence of PrP^Sc) and subsequently purified by treatment with 2% (wt/vol) N-lauroyl sarcosine (in 0.1 M Tris [pH 7.4]), allowing sedimentation of only the proteinase-K-resistant, detergent-insoluble fraction of PrP (PrP^Sc). Samples were subjected to electrophoresis through 7.4% polyacrylamide gels (Bio-Rad, Hemel Hempstead, United Kingdom) and transferred to polyvinylidene difluoride membranes (Bio-Rad) by semidy blotting. PrP was detected with the PrP-specific rabbit polyclonal antiserum 1B3 (15) followed by alkaline phosphatase-conjugated goat anti-rabbit antiserum (Jackson ImmunoResearch Laboratories Inc., West Grove, Pa.), and bound alkaline phosphatase activity was detected with SigmaFast NBT/BCIP solution (Sigma, Poole, Dorset, United Kingdom).

Ultrastructural immunohistochemistry. Spleen fragments were immersion fixed in 0.5% paraformaldehyde-0.5% glutaraldehyde for 24 h at 4°C, postfixed in osmium tetroxide, dehydrated, and embedded in araldite. Serial 65-nm-thick sections were then placed on 300-mesh nickel grids and prepared as previously described (12). Briefly, PrP was detected by staining with the PrP-specific rabbit polyclonal antiserum 1A8 (14) followed by Auroprobe 1-nm colloidal gold. Sections were then postfixed in 2.5% glutaraldehyde in phosphate-buffered saline, and staining was enhanced with immunogold silver stain. The grids were then counterstained with uranyl acetate and lead citrate.

Previous studies have shown that the combination of fixatives and pretreatments required for the preparation of tissue for electron microscopy by this method destroys PrP^Sc immunoreactivity and reveals only disease-specific PrP accumulations (23).

Statistical analysis. Incubation period data are expressed as means ± standard errors of the mean, and significant differences between incubation periods were sought by one-way analysis of variance with Minitab for Windows (Minitab Inc., State College, Pa.).

RESULTS

Effect of huTNFR:Fc treatment on FDC status. A blockade of the TNF-α signaling pathway was achieved by a single i.p. injection of 100 μg of huTNFR:Fc (34). This fusion protein binds TNF-α with high affinity and acts as an antagonist of TNF-α biological activity in vivo assays in mice (34, 47). Here, within 2 days of treatment of mice with huTNFR:Fc, a significant reduction in staining for the FDC markers FDC-M2 and CD35 was observed in lymphoid follicles of the spleen (Fig. 1). Furthermore, FDC-M2 and CD35 expression was absent 5 (data not shown) and 7 (Fig. 1) days after treatment with huTNFR:Fc. The cellular isomer of the prion protein, PrP^C, is expressed by FDCs in uninfected mice (Fig. 1) (5, 29, 33). Likewise, PrP^C expression was also markedly reduced within 2 days of treatment and undetectable 5 (data not shown) and 7 (Fig. 1) days after treatment with huTNFR:Fc. The effects of huTNFR:Fc treatment on FDC status were temporary, as PrP^C-expressing FDC networks were detected in the spleen 14 days after treatment (Fig. 1). Treatment of mice with 100 μg of polyclonal hu-Ig as a control had no adverse effect on FDC status (Fig. 1). In some follicles from hu-Ig-treated mice, there appeared to be increases in the size of the FDC network and the level of PrP^C expression 14 days after treatment compared to values for follicles analyzed 2 and 7 days after treatment (Fig. 1). This may be indicative of a germinal-center response to hu-Ig.

Ultrastructural analysis of the effect of huTNFR:Fc treatment on FDC status. Mice were treated with huTNFR:Fc or hu-Ig 38 days after i.p. injection with scrapie, and PrP deposition in the spleen was analyzed 7 days later by light-microscopic and ultrastructural immunohistochemical methods. As expected, in spleens of control-treated mice, abundant disease-specific PrP^C staining in association with FDCs was detected by light microscopy (Fig. 2a and c). Immunoelectron microscopic analysis confirmed that these PrP^C accumulations were disease specific and were found in association with electron-dense material at the surface of highly convoluted FDC dendrites (Fig. 2e and f), as previously reported (23). In some follicles, individual fibrils consistent with the dimensions of amyloid fibrils were present in association with FDCs (data not shown). Disease-specific PrP^C accumulations were also detected within secondary lysosomes of tingible body macrophages (Fig. 2e).

Mice were treated with huTNFR:Fc 38 days after scrapie injection, and abundant PrP labeling was still apparent in the spleen 7 days after treatment (Fig. 2d) despite a temporary absence of mature FDCs (Fig. 2b). Ultrastructural analysis revealed that the centers of secondary lymphoid follicles in spleens from huTNFR:Fc-treated mice showed marked degenerative changes compared with those from hu-Ig-treated control mice. Severe and extensive lymphocyte apoptosis was noted (Fig. 2g), and large numbers of highly reactive macrophages containing degenerative cellular material were also present in these sites (Fig. 2h). In many cases, whole apoptotic B lymphocytes could also be identified within these macrophages. At the ultrastructural level, FDC networks were identified but their processes appeared immature (Fig. 2i) and lacked the highly convoluted characteristics observed for those of hu-Ig-treated control mice (Fig. 2f). The immature nature of these FDC dendrites was consistent with the loss of expression of FDC-specific markers following huTNFR:Fc treatment (Fig. 1 and 2). Although a few mature FDC processes were identified at the ultrastructural level, it was not possible to
Effect of huTNFR:Fc treatment on scrapie pathogenesis.

Mice were given a single i.p. injection of huTNFR:Fc (or hu-Ig as a control) at one of three different times relative to scrapie challenge: 5 days before scrapie injection, so mature FDCs would be absent in lymphoid tissues at the time of scrapie injection; 14 days after scrapie injection, soon after the onset of scrapie replication in lymphoid tissues; or 38 days after scrapie injection, when high levels of scrapie infectivity are present in lymphoid tissues (5, 30). When groups of six mice were challenged with the ME7 scrapie strain by direct i.c. injection into the CNS, treatment with huTNFR:Fc 5 days before or 14 days after scrapie challenge had no effect on the incubation period of the disease (164 to 172 days; Fig. 3a) or pathology within the brain (data not shown) compared with those of controls. These findings demonstrate that the blockade of the TNFR signaling pathway did not affect scrapie pathogenesis once disease was established in the CNS.

When treated with huTNFR:Fc before or shortly after peripheral (i.p.) injection with scrapie, mice developed neurological disease much later than did the hu-Ig-treated controls. The most significant effect was observed when mice were treated 5 days before i.p. scrapie injection (Fig. 3b). For example, following injection with a moderate dose of scrapie (20 μl of a 1.0% scrapie brain homogenate), all control-treated mice succumbed to disease, with a mean incubation period of 255 ± 15 days (n = 8), whereas those treated with huTNFR:Fc developed disease 47 days later, with a mean incubation period of 302 ± 7 days (P < 0.01; n = 8; Fig. 3b). Likewise, when treated with huTNFR:Fc before injection with a 10-fold-lower scrapie dose (20 μl of a 0.1% scrapie brain homogenate), mice developed neurological disease with a mean incubation period of 353 ± 4 days (n = 9), which was 38 days longer than the mean incubation period of the hu-Ig-treated controls (315 ± 7 days; P < 0.001; n = 9; Fig. 3b). Despite these highly significant prolongations of the incubation period, little effect on disease susceptibility was observed following treatment with huTNFR:Fc prior to injection with a low dose of scrapie (20 μl of a 0.01% scrapie brain homogenate): 7 of 9 huTNFR:Fc-treated mice remained free of scrapie disease 500 days after inoculation, compared to 5 of 9 control mice (Fig. 3b).

An increase in survival time was also observed when treatment with huTNFR:Fc was delayed until 14 days after i.p. injection with a moderate dose of scrapie (Fig. 3c). In this instance, mice developed neurological disease with a mean incubation period of 281 ± 7 days (n = 8), which was 19 days longer than the mean incubation period of the hu-Ig-treated controls (262 ± 8.0 days; n = 8). However, treatment with huTNFR:Fc 38 days after injection, a time when high levels of infectivity agents have already accumulated in the spleen (5,
Scrapie infectivity and PrP<sub>Sc</sub> accumulation in the spleen. Within 70 days of a peripheral injection of untreated mice with the ME7 scrapie strain, high levels of infectivity and the disease-specific isomer of the prion protein, PrP<sup>Sc</sup>, accumulate within lymphoid tissues (5, 12, 28, 30). In this study, spleens were taken from each control and huTNFR:Fc treatment group 70 days after i.p. injection with a moderate dose of scrapie and halved. PrP<sup>Sc</sup> accumulation was determined in one half by immunoblot analysis, while the scrapie infectivity titer was estimated in the other half by bioassay in groups of indicator mice. As expected, all spleens from control mice treated with hu-Ig 5 days before or 14 or 38 days after scrapie challenge contained high infectivity titers (5.0 to 5.3 log i.c. ID<sub>50</sub>/g, as estimated by incubation period assay; Fig. 4) and abundant detergent-insoluble, relatively proteinase-K-resistant PrP<sup>Sc</sup> (Fig. 4). However, following treatment of mice with huTNFR:Fc 5 days before scrapie challenge, PrP<sup>Sc</sup> was less abundant in the spleen 70 days postinfection (Fig. 4a, lanes 4 and 6). In contrast, the infectivity titers were as high as those detected in spleens from hu-Ig-treated controls, suggesting that the accumulation of PrP<sup>Sc</sup> in the spleen lags behind replication of infectivity during the early stages of infection, as observed in previous studies (12, 28).

When treatment was delayed until 14 or 38 days after scrapie challenge, no differences in the accumulation of infectivity or abundance of PrP<sup>Sc</sup> in the spleen were detected between control- and huTNFR:Fc-treated mice when measured 70 days after scrapie challenge (Fig. 4b and c).
FIG. 2—Continued.
DISCUSSION

Here we have shown that a single treatment of mice with huTNFR:Fc before or shortly after a peripheral scrapie injection significantly extended survival time compared to that of control-treated mice. Our studies also demonstrated that treatment prior to peripheral exposure decreased the early accumulation of disease-specific PrPSc within the spleen. These effects coincided with a temporary dedifferentiation of mature PrP-expressing FDCs in the spleen following treatment with huTNFR:Fc. Taken together, these results are consistent with previous findings that in the absence of mature FDCs in lymphoid tissues, neuroinvasion following peripheral injection with scrapie is impaired (5, 29, 30). Surprisingly, a single treatment with huTNFR:Fc had little influence on disease susceptibility following low-dose scrapie challenge. Nevertheless, TNF-α blockade over longer periods may present a potential strategy for intervention in peripherally acquired TSEs.

Secretion of TNF-α has been implicated in the development of neuropathology in several human inflammatory, infectious, and autoimmune disorders (40). Although TNF-α expression has been reported to occur in the brains of mice showing clinical signs of scrapie (9), studies using TNF-α−/− mice (30) and TNFR-1-deficient mice (25) suggest that this cytokine signaling pathway alone is not directly involved in the development of neuropathology in TSEs. Due to its high molecular weight, huTNFR:Fc would be unlikely to cross the blood-brain barrier.
barrier and inhibit TNF-α signaling within the brain. Treatment with huTNFR:Fc in this study had no effect on survival time or neuropathology when mice were injected with scrapie directly into the CNS, confirming that the effects of treatment on TSE pathogenesis operate at a peripheral stage prior to neuroinvasion. Our studies suggest this is most likely due to a temporary interference with the integrity of FDCs, although effects of huTNFR:Fc treatment on other cell types in the spleen cannot be entirely excluded. However, the increased survival time following treatment with huTNFR:Fc 14 days after scrapie injection (Fig. 3b) and the recent demonstration that membrane lymphotoxin, not TNF-α, regulates the migration of dendritic cells in the spleen (48) suggest that it is unlikely that the effects of huTNFR:Fc treatment on scrapie pathogenesis are due to impaired cell trafficking from the site of scrapie challenge to the spleen.

Light-microscopical analysis demonstrated that mature PrP-expressing FDCs were temporarily absent in the spleen soon after treatment with huTNFR:Fc. Several hypotheses could explain the fate of FDCs following huTNFR:Fc treatment: (i) FDCs temporarily revert to an immature state that affects their function and phenotype; (ii) the chemokine gradients responsible for the organization of cell populations within the germinal center are altered (36), and as a consequence the FDCs disperse; or (iii) in the absence of stimulation from TNF-α, FDCs undergo apoptosis. We consider the first hypothesis most likely, as despite a temporary absence of FDC-M2, CD35, and PrP expression by FDCs, immature FDC processes were detected at the ultrastructural level, suggesting that these cells had reverted to a dedifferentiated state. Antigens are trapped and retained on the surface of FDCs through interactions between complement components and cellular complement receptors (37, 39). The loss of expression of complement receptor 1 (CD35; Fig. 1) and substantially decreased abundance of complement component C3 (data not shown) in lymphoid follicles of treated mice implied that these immature FDC processes had an impaired ability to retain antigens (31). Recent studies have demonstrated that C1q, C3, and complement receptors play an important role in the localization of TSE infectious agents to FDCs (26, 28). Therefore, it is unlikely that during the period of dedifferentiation following treatment with huTNFR:Fc, these immature FDC processes would have the potential to acquire TSE infectivity. Occasionally a few mature FDC processes were detected in the spleen by ultrastructural analysis 7 days after treatment (data not shown). These may represent FDCs in the process of regeneration, but it is also plausible that these were FDCs that were participating in strong antigenic responses and whose state of differentiation was unaffected by treatments which inhibit the TNFR signaling pathway (31).

Ultrastructural analysis of secondary lymphoid follicles from huTNFR:Fc-treated mice revealed other associated degenerative changes. FDCs provide important costimulatory factors which prevent B lymphocytes from undergoing apoptosis (18). Therefore, the detection of severe and extensive lymphocyte apoptosis following treatment with huTNFR:Fc suggested that this was most likely due to a loss of mature FDCs. Many of these apoptotic B lymphocytes were identified whole within tingible body macrophages which scavenge apoptotic lymphocytes and are considered to regulate the germinal-center reaction (42). The increased survival time following treatment with huTNFR:Fc is unlikely to be directly related to a loss of B lymphocytes by apoptosis, as ME7 scrapie pathogenesis is unaffected in mice with impaired germinal-center B-lymphocyte development (30). However, the effects of treatment on disease susceptibility could be indirectly related to a loss of cytokine stimuli from B lymphocytes, which leads to FDC dedifferentiation.

Within 70 days of a peripheral injection of immunocompetent mice with the ME7 scrapie strain, high levels of infectivity
titers and abundant PrPSc are detected in the spleen (5, 12, 28, 30). Here, when mice were given huTNFR:Fc before scrapie challenge, low levels of PrPSc were detected in the spleen 70 days postinoculation, approximately 50 days after the expected reappearance of mature FDCs. In the absence of mature FDCs at the time of scrapie challenge, it is likely that PrPSc and infectivity from the inoculum persist in the spleen but that a significant proportion is destroyed, for example by macrophages (3, 10). This effect would significantly delay both the onset of replication when the FDCs reappear within 14 days of treatment and the subsequent transfer of infectivity via peripheral nerves (19) into the CNS. Interestingly, infectivity titers in spleens from huTNFR:Fc-treated mice were the same as those from hu-Ig-treated controls, implying that the accumulation of PrPSc in the spleen lags behind the replication of infectivity during the early stages of infection (28). These experiments also suggest that the time interval during which the FDCs were unable to acquire and replicate scrapie was insufficient to allow macrophages adequate time to destroy most of the infectious agents, as huTNFR:Fc treatment had little, if any, effect on disease susceptibility.

Further experiments will extend whether it is possible to extend the period of FDC dedifferentiation beyond that described in this report through prolonged treatment with multiple doses of huTNFR:Fc. Such an approach may reduce the accumulation of scrapie infectivity in the spleen and further delay or prevent the development of disease in the CNS. However, a prolonged blockade of proinflammatory cytokines such as TNF-α may cause serious side effects, including increased susceptibility to other infectious microorganisms, increased incidence of malignancies, or induction of autoimmune disease. A therapeutic blockade of TNF-α has been used to successfully treat rheumatoid arthritis and Crohn’s disease in humans, where this cytokine plays a critical role in mediating inflammation (22, 32). The experience of long-term treatment of human rheumatoid arthritis patients with TNF-α antagonists suggests that they are safe and well tolerated (22, 32).

The detection of infectivity in lymphoid tissues and of PrPSc in association with FDCs from patients with vCJD (6, 21) and sheep with natural scrapie (1, 20, 45) suggests that these TSEs also share a similar requirement for FDCs. Therefore, the experiments described in this report and those of others suggest that treatments which temporally interfere with the integrity (29, 35) or immune complex trapping function (28) of FDCs offer a potential approach for early intervention in peripherally acquired TSEs.

ACKNOWLEDGMENTS

We thank Irene McConnell, Dawn Drummond, and Emma Murdoch (Institute for Animal Health, Neuropathogenesis Unit, Edinburgh, United Kingdom) for excellent technical support; Immunex Corp. (Seattle, Wash.) for provision of huTNFR:Fc; Christine Farquhar (Institute for Animal Health, Neuropathogenesis Unit) for helpful discussion and provision of 1A8 and 1B3 polyclonal antisera; Marie Farquhar (Institute for Animal Health, Neuropathogenesis Unit) for help; Jeffrey Browning (Biogen Inc., Cambridge, Mass.) for provision of hu-Ig. This work was supported by funding from the Medical Research Council and the Biotechnology and Biological Sciences Research Council.

REFERENCES
